{
    "clinical_study": {
        "@rank": "139815", 
        "brief_summary": {
            "textblock": "The primary objectives are a) to establish the maximum tolerated dose (MTD) of gemtuzumab\n      ozogamicin in combination with cytarabine and daunorubicin, and b) to assess the safety of\n      gemtuzumab ozogamicin when given concurrently with cytarabine and daunorubicin."
        }, 
        "brief_title": "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All adult patients with relapsed or refractory AML, as well as younger de novo AML\n             patients are eligible for the study\n\n          -  Relapsed, refractory, and de novo AML patients are allowed in Phase I of this study\n\n          -  Phase II will only allow enrollment of younger de novo AML\n\n        Exclusion Criteria:\n\n          -  AML following an antecedent hematologic disorder (myelodysplasia or\n             myeloproliferation) of greater than 2 months duration\n\n          -  De novo patients with M3 AML\n\n          -  AML secondary to exposure to chemotherapy or radiation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 17, 2002", 
        "id_info": {
            "nct_id": "NCT00037583", 
            "org_study_id": "0903B1-206"
        }, 
        "intervention": {
            "intervention_name": "Gemtuzumab Ozogamicin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemtuzumab"
        }, 
        "keyword": [
            "Acute", 
            "Myeloid", 
            "Leukemia"
        ], 
        "lastchanged_date": "August 20, 2009", 
        "official_title": "A Dose-Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (go) Given in Combination With Cytarabine and Daunorubicin in Relapsed or Refractory Patients and in Younger de Novo Patients With Acute Myeloid Leukemia (AML)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037583"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2009"
    }, 
    "geocoordinates": {}
}